Cargando…

Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials

INTRODUCTION: The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for systematically identifying and synthesising the available evidence on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qiancheng, Ye, Daoli, Xudong, Zhao, Wang, Qingfeng, Gou, Hongfeng, Luo, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124296/ https://www.ncbi.nlm.nih.gov/pubmed/37080619 http://dx.doi.org/10.1136/bmjopen-2022-070972

Ejemplares similares

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2020)

Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials
por: Ma, Ji, et al.
Publicado: (2021)

Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis
por: Hu, Qiancheng, et al.
Publicado: (2022)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials
por: Xie, Ming, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol
por: Hu, Qiancheng, et al.
Publicado: (2021)

Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer
por: Jacobs, Jamie M, et al.
Publicado: (2021)

An unmet need: tailoring extended adjuvant endocrine therapy
por: Bianchini, G, et al.
Publicado: (2013)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
por: Zeng, Erwei, et al.
Publicado: (2022)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Optimal duration of adjuvant endocrine therapy: how to apply the newest data
por: Wimmer, Kerstin, et al.
Publicado: (2017)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

An optimum LEP position
por: Plass, Günther
Publicado: (1982)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
por: Tolaney, Sara M., et al.
Publicado: (2022)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Corticosteroids for COVID-19: the search for an optimum duration of therapy
por: Mishra, Gyanshankar P, et al.
Publicado: (2021)

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
por: El Sayed, Rola, et al.
Publicado: (2019)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol
por: Vergauwen, Glenn, et al.
Publicado: (2023)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
por: Qin, Ruoyan, et al.
Publicado: (2023)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
por: Xie, Yuxin, et al.
Publicado: (2022)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023)

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
por: Sella, Tal, et al.
Publicado: (2023)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_497dqksm505sa6n451rrqmtf6v